Biotech Values

[DewDiligence]

Addendum—ENTA’s COVID-19 PR is silent about expected Mavyret royalties from ABBV. ENTA is not in a position to comment on this until ABBV does.

I expect some degradation in Mavyret royalties from the COVID-19 outbreak, as there will certainly be fewer patients starting HCV drugs during the next several months. However, this patient-start shortfall ought to be temporary insofar as people who defer HCV treatment are still going to need it, unless they die in the interim.